American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Phase 3 ELOQUENT-2 Study: Extended 4-Year Follow-Up of Elotuzumab plus Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in RRMM

ASCO 2017 – Multiple Myeloma

The 4-year follow-up of the ELOQUENT-2 study examining elotuzumab plus lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) shows sustained safety and efficacy results. Read More ›

Daratumumab, Bortezomib and Dexamethasone versus Bortezomib and Dexamethasone in RRMM: Efficacy and Safety Update (CASTOR)

ASCO 2017 – Multiple Myeloma

Researchers from the CASTOR trial provided an update on the efficacy and safety of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›

Trends in Survival and Costs Among US Patients with Multiple Myeloma

ASCO 2017 – Multiple Myeloma

This study examined the trends in survival and healthcare costs of US patients with multiple myeloma from 2006 to 2014. Read More ›

Comparative Efficacy of MM Therapies for Treatment of First Relapse: A Systematic Literature Review and Network Meta-Analysis

ASCO 2017 – Multiple Myeloma

A systematic literature review and network meta-analysis were conducted to determine the comparative efficacy of multiple myeloma (MM) therapies for treating first relapse. Read More ›

Racial Differences in Abnormalities by FISH in Minorities with Multiple Myeloma: A Single-Center Experience

ASCO 2017 – Multiple Myeloma

This study provides a closer look at the racial differences in fluorescence in situ hybridization (FISH) abnormalities in minorities with multiple myeloma. Read More ›

Cost-Effectiveness of Carfilzomib, Ixazomib, Elotuzumab, or Daratumumab with Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in RRMM

ASCO 2017 – Multiple Myeloma

The combination of daratumumab plus lenalidomide and dexamethasone is associated with the greatest progression-free survival life-years and quality-adjusted life-years versus combinations including carfilzomib, ixazomib, and elotuzumab with relapsed/refractory multiple myeloma (RRMM). Read More ›

Nivolumab with Azacytidine in Patients with Relapsed AML

ASCO 2017 – AML

The PD-1 inhibitor nivolumab, in combination with azacytidine, may represent an effective treatment option for some patients with relapsed acute myeloid leukemia (AML).

ASCO 2017 – AML

Patients with acute myeloid leukemia (AML) and TP53 mutations may benefit from certain types of low-intensity chemotherapy.

ASCO 2017 – AML

In a phase 1 study, the mIDH2 inhibitor enasidenib showed promise as a potential emerging therapy for patients with relapsed or refractory acute myeloid leukemia (AML).

ASCO 2017 – AML

Synthetic control arms may represent an efficient, cost-effective way to evaluate early end points in clinical trials.

American Society of Clinical Oncology (ASCO)

Page 18 of 33